polyethylene glycols


Summary: Polymers of ETHYLENE OXIDE and water and their ethers. They vary in consistency from liquid to solid, depending on the molecular weight, indicated by a number following the name. They are used as SURFACTANTS, dispersing agents, solvents, ointment and suppository bases, vehicles, and tablet excipients. Some specific groups are lauromagrogols, nonoxynols, octoxynols and poloxamers.

Top Publications

  1. ncbi Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance
    Dongliang Ge
    Institute for Genome Sciences and Policy, Center for Human Genome Variation, Duke University, Durham, North Carolina 27708, USA
    Nature 461:399-401. 2009
  2. pmc Boceprevir for untreated chronic HCV genotype 1 infection
    Fred Poordad
    Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    N Engl J Med 364:1195-206. 2011
  3. ncbi Telaprevir for previously untreated chronic hepatitis C virus infection
    Ira M Jacobson
    Weill Cornell Medical College and Center for the Study of Hepatitis C, New York, NY 10021, USA
    N Engl J Med 364:2405-16. 2011
  4. ncbi Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection
    Michael W Fried
    University of North Carolina, Chapel Hill 27599, USA
    N Engl J Med 347:975-82. 2002
  5. ncbi IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy
    Vijayaprakash Suppiah
    Storr Liver Unit, University of Sydney, Sydney, Australia
    Nat Genet 41:1100-4. 2009
  6. pmc Boceprevir for previously treated chronic HCV genotype 1 infection
    Bruce R Bacon
    Saint Louis University School of Medicine, St Louis, Mo 63110 0250, USA
    N Engl J Med 364:1207-17. 2011
  7. ncbi Telaprevir for retreatment of HCV infection
    Stefan Zeuzem
    Johann Wolfgang Goethe University Medical Center, Frankfurt am Main, Germany
    N Engl J Med 364:2417-28. 2011
  8. ncbi Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial
    M P Manns
    Division of Gastroenterology and Hepatology, Medical School of Hannover, Hannover, Germany
    Lancet 358:958-65. 2001
  9. pmc Response-guided telaprevir combination treatment for hepatitis C virus infection
    Kenneth E Sherman
    Division of Digestive Diseases, University of Cincinnati College of Medicine, Cincinnati, OH 45267 0595, USA
    N Engl J Med 365:1014-24. 2011
  10. ncbi Preliminary study of two antiviral agents for hepatitis C genotype 1
    Anna S Lok
    Department of Internal Medicine, Division of Gastroenterology, 3912 Taubman Center, SPC 5362, University of Michigan Medical Center, Ann Arbor, MI 48109, USA
    N Engl J Med 366:216-24. 2012

Detail Information

Publications318 found, 100 shown here

  1. ncbi Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance
    Dongliang Ge
    Institute for Genome Sciences and Policy, Center for Human Genome Variation, Duke University, Durham, North Carolina 27708, USA
    Nature 461:399-401. 2009
  2. pmc Boceprevir for untreated chronic HCV genotype 1 infection
    Fred Poordad
    Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    N Engl J Med 364:1195-206. 2011
    ..The rate of sustained virologic response has been below 50% in cases of HCV genotype 1 infection. Boceprevir, a potent oral HCV-protease inhibitor, has been evaluated as an additional treatment in phase 1 and phase 2 studies...
  3. ncbi Telaprevir for previously untreated chronic hepatitis C virus infection
    Ira M Jacobson
    Weill Cornell Medical College and Center for the Study of Hepatitis C, New York, NY 10021, USA
    N Engl J Med 364:2405-16. 2011
  4. ncbi Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection
    Michael W Fried
    University of North Carolina, Chapel Hill 27599, USA
    N Engl J Med 347:975-82. 2002
    ..We compared the efficacy and safety of peginterferon alfa-2a plus ribavirin, interferon alfa-2b plus ribavirin, and peginterferon alfa-2a alone in the initial treatment of chronic hepatitis C...
  5. ncbi IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy
    Vijayaprakash Suppiah
    Storr Liver Unit, University of Sydney, Sydney, Australia
    Nat Genet 41:1100-4. 2009
    ..These data suggest that host genetics may be useful for the prediction of drug response, and they also support the investigation of the role of IL28B in the treatment of HCV and in other diseases treated with IFN-alpha...
  6. pmc Boceprevir for previously treated chronic HCV genotype 1 infection
    Bruce R Bacon
    Saint Louis University School of Medicine, St Louis, Mo 63110 0250, USA
    N Engl J Med 364:1207-17. 2011
    ..Boceprevir, a protease inhibitor that binds to the HCV nonstructural 3 (NS3) active site, has been suggested as an additional treatment...
  7. ncbi Telaprevir for retreatment of HCV infection
    Stefan Zeuzem
    Johann Wolfgang Goethe University Medical Center, Frankfurt am Main, Germany
    N Engl J Med 364:2417-28. 2011
    ..Up to 60% of patients with hepatitis C virus (HCV) genotype 1 infection do not have a sustained virologic response to therapy with peginterferon alfa plus ribavirin...
  8. ncbi Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial
    M P Manns
    Division of Gastroenterology and Hepatology, Medical School of Hannover, Hannover, Germany
    Lancet 358:958-65. 2001
    ..In this randomised trial, peginterferon alfa-2b plus ribavirin was compared with interferon alfa-2b plus ribavirin...
  9. pmc Response-guided telaprevir combination treatment for hepatitis C virus infection
    Kenneth E Sherman
    Division of Digestive Diseases, University of Cincinnati College of Medicine, Cincinnati, OH 45267 0595, USA
    N Engl J Med 365:1014-24. 2011
    ..We designed a noninferiority trial (noninferiority margin, -10.5%) to compare rates of sustained virologic response among patients receiving two treatment durations...
  10. ncbi Preliminary study of two antiviral agents for hepatitis C genotype 1
    Anna S Lok
    Department of Internal Medicine, Division of Gastroenterology, 3912 Taubman Center, SPC 5362, University of Michigan Medical Center, Ann Arbor, MI 48109, USA
    N Engl J Med 366:216-24. 2012
    ..Patients with chronic hepatitis C virus (HCV) infection who have not had a response to therapy with peginterferon and ribavirin may benefit from the addition of multiple direct-acting antiviral agents to their treatment regimen...
  11. ncbi Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study
    Andri Rauch
    University Clinic of Infectious Diseases, University Hospital Bern and University of Bern, Bern, Switzerland
    Gastroenterology 138:1338-45, 1345.e1-7. 2010
    ..We performed a genome-wide association study to screen for host genetic determinants of HCV persistence and response to therapy...
  12. pmc Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo
    Omid C Farokhzad
    Department of Anesthesiology, Brigham and Women s Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 103:6315-20. 2006
    ..Dtxl alone had a survivability of only 14%. Saline and nanoparticles without drug were similarly nonefficacious. This report demonstrates the potential utility of nanoparticle-aptamer bioconjugates for a therapeutic application...
  13. ncbi Telaprevir for previously treated chronic HCV infection
    John G McHutchison
    Duke Clinical Research Institute and Duke University Medical Center, Durham, NC, USA
    N Engl J Med 362:1292-303. 2010
    ..Patients with genotype 1 hepatitis C virus (HCV) who do not have a sustained response to therapy with peginterferon alfa and ribavirin have a low likelihood of success with retreatment...
  14. ncbi Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C
    Masao Honda
    Department of Gastroenterology, Kanazawa University Graduate School of Medicine, Kanazawa, Japan
    Gastroenterology 139:499-509. 2010
    ..Multiple viral and host factors are related to the treatment response to pegylated-interferon and ribavirin combination therapy; however, the clinical relevance and relationship of these factors have not yet been fully evaluated...
  15. ncbi Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan
    Hiromitsu Kumada
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    J Hepatol 56:78-84. 2012
    ..To evaluate the efficacy and safety of telaprevir in combination with peginterferon-α2b (PEG-IFN) and ribavirin (RBV) in patients with chronic hepatitis C...
  16. ncbi Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer
    M E R O'Brien
    Kent Cancer Center, Maidstone, UK
    Ann Oncol 15:440-9. 2004
  17. ncbi Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir
    Christoph Sarrazin
    Klinik fur Innere Medizin II, Universitat des Saarlandes, Homburg Saar, Germany
    Gastroenterology 132:1767-77. 2007
    ..4A protease inhibitor, has shown strong antiviral activity in phase 1 clinical studies. Because of high levels of HCV replication and the low fidelity of HCV polymerase, selection of resistant isolates during therapy may occur...
  18. ncbi PEGylation, successful approach to drug delivery
    Francesco M Veronese
    Department of Pharmaceutical Sciences, Padua University, Italy
    Drug Discov Today 10:1451-8. 2005
    ..Thanks to these favorable properties, PEGylation now plays an important role in drug delivery, enhancing the potentials of peptides and proteins as therapeutic agents...
  19. ncbi IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection
    Martin Lagging
    Department of Infectious Diseases, University of Goteborg, Sweden
    Hepatology 44:1617-25. 2006
    ..Thus, pretreatment IP-10 analysis may prove helpful in decision-making regarding pharmaceutical intervention...
  20. ncbi Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C
    Michael T Dill
    Department of Biomedicine, Hepatology Laboratory, University of Basel, Basel, Switzerland
    Gastroenterology 140:1021-31. 2011
    ..We investigated whether IL28B genotype determines the constitutive expression of ISGs in the liver and compared the abilities of ISG levels and IL28B genotype to predict treatment outcome...
  21. ncbi Role of interleukin-28B polymorphisms in the treatment of hepatitis C virus genotype 2 infection in Asian patients
    Ming Lung Yu
    Department of Internal Medicine, Kaohsiung Municipal Ta Tung Hospital, Kaohsiung, Taiwan
    Hepatology 53:7-13. 2011
    ..99-1.00, P = 0.04). Nevertheless, the achievement of RVR was the single predictor of SVR with an OR of 19.37 (95% CI = 8.89-42.23, P < 0.001), whereas the rs8099917 genotypes played no role in achieving SVR with or without RVR...
  22. ncbi In vivo imaging of quantum dots encapsulated in phospholipid micelles
    Benoit Dubertret
    Center for Studies in Physics and Biology, Laboratory of Molecular Embryology, The Rockefeller University, 1230 York Avenue, New York, NY 10021, USA
    Science 298:1759-62. 2002
    ..Nanocrystal fluorescence could be followed to the tadpole stage, allowing lineage-tracing experiments in embryogenesis...
  23. ncbi Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C
    Maria Grazia Rumi
    AM Migliavacca Center for Liver Disease, First Division of Gastroenterology, Fondazione IRCCS Maggiore Hospital, Mangiagalli e Regina Elena, Universita degli Studi di Milano, Milan, Italy
    Gastroenterology 138:108-15. 2010
    ..Due to the lack of head-to-head studies, the 2 PegIFNs have not been directly compared. The endpoints of our study were safety and antiviral efficacy of the 2 regimens...
  24. ncbi Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B
    George K K Lau
    Department of Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong SAR, China
    N Engl J Med 352:2682-95. 2005
  25. ncbi Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial
    Paul Y Kwo
    Department of Medicine, Division of Gastroenterology Hepatology, Indiana University School of Medicine, Indianapolis, IN 46202 5121, USA
    Lancet 376:705-16. 2010
    ..We tested the efficacy of boceprevir, an NS3 hepatitis C virus oral protease inhibitor, when added to peginterferon alfa-2b and ribavirin...
  26. ncbi Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection
    John G McHutchison
    Duke Clinical Research Institute and Duke University, Durham, NC 27715, USA
    N Engl J Med 360:1827-38. 2009
    ..Telaprevir, a protease inhibitor specific to the HCV nonstructural 3/4A serine protease, rapidly reduced HCV RNA levels in early studies...
  27. pmc Photodegradable hydrogels for dynamic tuning of physical and chemical properties
    April M Kloxin
    Department of Chemical and Biological Engineering, University of Colorado, 424 UCB ECCH 111, Boulder, CO 80309, USA
    Science 324:59-63. 2009
  28. ncbi Acute toxicity and pharmacokinetics of 13 nm-sized PEG-coated gold nanoparticles
    Wan Seob Cho
    Division of Toxicologic Pathology, Department of Toxicological Research, National Institute of Toxicological Research, Korea Food and Drug Administration, 231 Jinhoungno Eunpyung ku, Seoul 122 704, Republic of Korea
    Toxicol Appl Pharmacol 236:16-24. 2009
    ..These findings of toxicity and kinetics of PEG-coated gold nanoparticles may have important clinical implications regarding the safety issue as PEG-coated gold nanoparticles are widely used in biomedical applications...
  29. ncbi Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose
    Stephanos J Hadziyannis
    Department of Medicine and Hepatology, Henry Dunant Hospital, Athens, Greece
    Ann Intern Med 140:346-55. 2004
    ..Treatment with pegylated interferon (peginterferon) and ribavirin for 48 weeks is more effective than conventional interferon and ribavirin in patients with chronic hepatitis C...
  30. pmc Rapid transport of large polymeric nanoparticles in fresh undiluted human mucus
    Samuel K Lai
    Department of Chemical and Biomolecular Engineering, The Johns Hopkins University, 3400 North Charles Street, Baltimore, MD 21218, USA
    Proc Natl Acad Sci U S A 104:1482-7. 2007
  31. ncbi Mediating tumor targeting efficiency of nanoparticles through design
    Steven D Perrault
    Institute of Biomaterials and Biomedical Engineering, Terrence Donnelly Centre for Cellular and Biomolecular Research, University of Toronto, 160 College Street, Toronto, ON, M5S 3E1, Canada
    Nano Lett 9:1909-15. 2009
    ..Our results provide design parameters for engineering nanoparticles for optimized tumor targeting of contrast agents and therapeutics...
  32. pmc Hepatic STAT1-nuclear translocation and interleukin 28B polymorphisms predict treatment outcomes in hepatitis C virus genotype 1-infected patients
    Tatsuo Miyamura
    Department of Medicine and Clinical Oncology, Graduate School of Medicine, Chiba University, Chiba, Japan
    PLoS ONE 6:e28617. 2011
  33. ncbi Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection
    Antonio Ascione
    Department of Gastroenterology, Liver Unit, Cardarelli Hospital, Napoli, Italy
    Gastroenterology 138:116-22. 2010
    ..This study compared the efficacy and safety of peginterferon alfa-2a and peginterferon alfa-2b, each in combination with ribavirin...
  34. ncbi Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer
    Bradley J Monk
    University of California at Irvine UCI and UCI Medical Center, Orange, CA 92868 3298, USA
    J Clin Oncol 28:3107-14. 2010
  35. ncbi Large-scale synthesis of uniform and extremely small-sized iron oxide nanoparticles for high-resolution T1 magnetic resonance imaging contrast agents
    Byung Hyo Kim
    World Class University program of Chemical Convergence for Energy and Environment, and School of Chemical and Biological Engineering, Seoul National University, Seoul 151 744, Korea
    J Am Chem Soc 133:12624-31. 2011
    ..High-resolution blood pool MR imaging using ESIONs enabled clear observation of various blood vessels with sizes down to 0.2 mm. These results demonstrate the potential of ESIONs as T(1) MRI contrast agents in clinical settings...
  36. ncbi PEG-modified gold nanorods with a stealth character for in vivo applications
    Takuro Niidome
    Department of Applied Chemistry, Faculty of Engineering, Kyushu University, 744 Motooka, Nishi ku, Fukuoka 819 0395, Japan
    J Control Release 114:343-7. 2006
    ..5 h after intravenous injection, whereas most of gold was detected in the liver in the case of original gold nanorods stabilized with CTAB...
  37. ncbi Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives
    Katrin Knop
    Lehrstuhl für Organische und Makromolekulare Chemie IOMC, Friedrich Schiller University Jena, Humboldtstrasse 10, 07745 Jena, Germany
    Angew Chem Int Ed Engl 49:6288-308. 2010
    ..These possible side effects will be discussed in this Review and alternative polymers will be evaluated...
  38. pmc "SMART" drug delivery systems: double-targeted pH-responsive pharmaceutical nanocarriers
    R M Sawant
    Department of Pharmaceutical Sciences, Northeastern University, Boston, Massachusetts 02115, USA
    Bioconjug Chem 17:943-9. 2006
    ..We consider this result as the first step in the development of multifunctional stimuli-sensitive pharmaceutical nanocarriers...
  39. ncbi Side effects of therapy of hepatitis C and their management
    Michael W Fried
    Division of Digestive Diseases, University of North Carolina, Chapel Hill, North Carolina 27599, USA
    Hepatology 36:S237-44. 2002
    ..Strategies to maximize adherence are being developed and, in the future, may include early identification of and therapy for depression and the selective use of hematopoietic growth factors to ameliorate hematologic abnormalities...
  40. ncbi Hepatitis C pharmacogenetics: state of the art in 2010
    Nezam H Afdhal
    Division of Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215, USA
    Hepatology 53:336-45. 2011
  41. ncbi Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C
    Gary L Davis
    Division of Hepatology, Baylor University Medical Center, Dallas, TX 75246, USA
    Hepatology 38:645-52. 2003
    ..Patients who fail to achieve EVR will not clear virus even if an additional 9 months of therapy is received. Therapy can be confidently discontinued in those cases...
  42. ncbi Peginterferon alfa-2a in patients with chronic hepatitis C
    S Zeuzem
    Klinikum der Johann Wolfgang Goethe Universitat, Frankfurt, Germany
    N Engl J Med 343:1666-72. 2000
    ..We compared the clinical effects of a regimen of peginterferon alfa-2a with those of a regimen of interferon alfa-2a in the initial treatment of patients with chronic hepatitis C...
  43. ncbi Supramolecular chemistry on water-soluble carbon nanotubes for drug loading and delivery
    Zhuang Liu
    Department of Chemistry, Stanford University, Stanford, California 94305, USA
    ACS Nano 1:50-6. 2007
    ..Such chemical partitioning should open up new opportunities in chemical, biological, and medical applications of novel nanomaterials...
  44. ncbi Effect of pegylation on pharmaceuticals
    J Milton Harris
    Nektar Therapeutics, 490 Discovery Drive, Huntsville, Alabama 35806, USA
    Nat Rev Drug Discov 2:214-21. 2003
    ..This article will review how PEGylation can result in drugs that are often more effective and safer, and which show improved patient convenience and compliance...
  45. ncbi Block copolymer micelles for drug delivery: design, characterization and biological significance
    K Kataoka
    Department of Materials Science, Graduate School of Engineering, The University of Tokyo, 7 3 1 Hongo, Bunkyo ku, Tokyo 113 8656, Japan
    Adv Drug Deliv Rev 47:113-31. 2001
    ..As an important perspective on carrier systems based on polymeric micelles, their feasibility as non-viral gene vectors is also summarized in this review article...
  46. pmc Molecular crowding creates an essential environment for the formation of stable G-quadruplexes in long double-stranded DNA
    Ke Wei Zheng
    Laboratory of Biochemistry and Biophysics, College of Life Sciences, Wuhan University, Wuhan, PR China
    Nucleic Acids Res 38:327-38. 2010
    ..This observation reveals a physical basis for the formation of stable G-quadruplexes in genome and supports its presence under the in vivo molecular crowding condition...
  47. ncbi Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size
    H Cabral
    Department of Bioengineering, Graduate School of Engineering, The University of Tokyo, Hongo, Bunkyo ku, Japan
    Nat Nanotechnol 6:815-23. 2011
    ..We also showed that the penetration and efficacy of the larger micelles could be enhanced by using a transforming growth factor-β inhibitor to increase the permeability of the tumours...
  48. ncbi Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab' certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a re-treatment extension
    K Reich
    Dermatologikum Hamburg, Stephansplatz 5, 20354 Hamburg, Germany
    Br J Dermatol 167:180-90. 2012
    ..Certolizumab pegol (CZP) is a PEGylated antitumour necrosis factor agent...
  49. pmc Arginine deprivation as a targeted therapy for cancer
    L Feun
    Hematology Oncology, University of Miami School of Medicine, 1201 N W 16th Street, Miami, FL 33136, USA
    Curr Pharm Des 14:1049-57. 2008
    ..This article reviews our laboratory and clinical experience as well as that from others with ADI-PEG20 as an antineoplastic agent. Future direction in utilizing this agent is also discussed...
  50. ncbi Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients
    Rami Moucari
    Service d Hepatologie, Hopital Beaujon, Clichy, France
    Hepatology 49:1151-7. 2009
    ..HBsAg loss was observed in three patients, all with SVR...
  51. ncbi Discovery and development of telaprevir: an NS3-4A protease inhibitor for treating genotype 1 chronic hepatitis C virus
    Ann D Kwong
    Vertex Pharmaceuticals, Cambridge, Massachusetts, USA
    Nat Biotechnol 29:993-1003. 2011
    ..Lessons learned from the development of telaprevir suggest that makers of innovative medicines cannot rely solely on traditional drug discovery metrics, but must develop innovative, scientifically guided pathways for success...
  52. ncbi Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse
    Eric Pujade-Lauraine
    University Paris Descartes, Assistance Publique Hopitaux de Paris, Hopital Hotel Dieu, Paris, France
    J Clin Oncol 28:3323-9. 2010
  53. ncbi Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C
    Y F Liaw
    Liver Research Unit, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taipei, Taiwan
    Hepatology 54:1591-9. 2011
    ..Adverse events were typical of those associated with PEG-IFNα-2a...
  54. ncbi DNA condensation
    V A Bloomfield
    Department of Biochemistry, University of Minnesota, St Paul 55108, USA
    Curr Opin Struct Biol 6:334-41. 1996
    ..DNA condensed with cationic liposomes is an efficient agent for the transfection of eukaryotic cells, with considerable potential interest for gene therapy...
  55. pmc Arginine deiminase as a novel therapy for prostate cancer induces autophagy and caspase-independent apoptosis
    Randie H Kim
    Department of Biological Chemistry, Division of Surgical Oncology, Center for Biophotonics and Science Technology, University of California at Davis, Sacramento, California 95817, USA
    Cancer Res 69:700-8. 2009
    ..Finally, a tissue microarray of 88 prostate tumor samples lacked expression of ASS, indicating ADI-PEG20 is a potential novel therapy for the treatment of prostate cancer..
  56. pmc Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial
    J Smolen
    Department of Internal Medicine III, Medical University of Vienna and 2nd Department of Medicine, Hietzing Hospital, Austria
    Ann Rheum Dis 68:797-804. 2009
    ..Certolizumab pegol is a PEGylated tumour necrosis factor inhibitor...
  57. ncbi Micellar nanocontainers distribute to defined cytoplasmic organelles
    Radoslav Savic
    Department of Pharmacology and Therapeutics, McGill University, Montreal, QC, H3G 1Y6, Canada
    Science 300:615-8. 2003
    ..These micelles may thus be worth exploring for their potential to selectively deliver drugs to specified subcellular targets...
  58. ncbi Cell-penetrating quantum dots based on multivalent and endosome-disrupting surface coatings
    Hongwei Duan
    Department of Biomedical Engineering, Emory University, Atlanta, Georgia, USA
    J Am Chem Soc 129:3333-8. 2007
    ..These insights are important toward the design and development of nanoparticle agents for intracellular imaging and therapeutic applications...
  59. ncbi [Comparison of therapeutic results between combination therapy of peginterferon alpha-2a plus ribavirin and interferon alpha-2b plus ribavirin according to treatment duration in patients with chronic hepatitis C]
    Heon Ju Lee
    Department of Internal Medicine, Yeungnam University College of Medicine, Daegu, Korea
    Korean J Hepatol 14:46-57. 2008
  60. ncbi Micellar carriers based on block copolymers of poly(epsilon-caprolactone) and poly(ethylene glycol) for doxorubicin delivery
    Xintao Shuai
    Department of Biomedical Engineering, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, OH 44106, USA
    J Control Release 98:415-26. 2004
    ..Consistent with the in vitro release and CLSM results, a cytotoxicity study demonstrated that DOX-loaded micelles exhibited time-delayed cytotoxicity in human MCF-7 breast cancer cells...
  61. ncbi Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in Asian patients
    Dong H Sinn
    Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
    J Gastroenterol Hepatol 26:1374-9. 2011
    ..A single nucleotide polymorphism near the interleukin-28B (IL28B) gene has been shown to predict hepatitis C virus (HCV) treatment response. We aim to determine the role of the IL28B genotype in Asian patients...
  62. pmc A randomised phase II study of pegylated arginine deiminase (ADI-PEG 20) in Asian advanced hepatocellular carcinoma patients
    T S Yang
    Department of Internal Medicine, Chang Gung Memorial Hospital, Linkou Medical Center, Chang Gung University, Taoyuan 33305, Taiwan
    Br J Cancer 103:954-60. 2010
    ..This study aims to investigate the efficacy and pharmacodynamics of pegylated arginine deiminase (ADI-PEG 20), a systemic arginine deprivation agent, in Asian HCC patients...
  63. ncbi Improved therapeutic activity of folate-targeted liposomal doxorubicin in folate receptor-expressing tumor models
    Alberto Gabizon
    Experimental Oncology Laboratory, Shaare Zedek Medical Center, 11 Shmuel Bayit Street, 7th Floor, PO Box 3235, Jerusalem 91031, Israel
    Cancer Chemother Pharmacol 66:43-52. 2010
    ..Targeting liposomes to the FR has been proposed as a way to enhance the effects of liposome-based chemotherapy...
  64. ncbi Peginterferon alpha-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C: systematic review of randomized trials
    Tahany Awad
    Cochrane Hepato Biliary Group, Copenhagen Trial Unit, Center for Clinical Intervention Research, Department 3344, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
    Hepatology 51:1176-84. 2010
    ..The meta-analysis of adverse events leading to treatment discontinuation included 11 trials and revealed no significant differences between the two peginterferons...
  65. ncbi Peginterferon and ribavirin for chronic hepatitis C
    Jay H Hoofnagle
    Liver Disease Research Branch, Division of Digestive Diseases and Nutrition, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, USA
    N Engl J Med 355:2444-51. 2006
  66. ncbi Emerging PEGylated drugs
    Jung Seok Kang
    Sungkyunkwan University, College of Pharmacy, Drug Targeting Laboratory, Suwon 440 746, Korea
    Expert Opin Emerg Drugs 14:363-80. 2009
    ..This active research in the PEGylation field and the continued growth of the biopharmaceutical market predicts that PEGylated drugs have a bright future...
  67. pmc PEEK biomaterials in trauma, orthopedic, and spinal implants
    Steven M Kurtz
    Exponent, Inc, 3401 Market Street, Suite 300, Philadelphia, PA 19104, USA
    Biomaterials 28:4845-69. 2007
    ..For mature fields, such as total joint replacements and fracture fixation implants, radiolucency is an attractive but not necessarily critical material feature...
  68. ncbi Glycyrrhetinic acid-modified chitosan/poly(ethylene glycol) nanoparticles for liver-targeted delivery
    Qin Tian
    Key Laboratory of Functional Polymer Materials, Ministry of Education, Institute of Polymer Chemistry, Nankai University, Tianjin 300071, PR China
    Biomaterials 31:4748-56. 2010
    ..HCl (DOX.HCl) and the DOX-loaded CTS/PEG-GA nanoparticles were 47 and 79 ng/mL, respectively. Moreover, the DOX-loaded CTS/PEG-GA nanoparticles could effectively inhibit tumor growth in H22 cell-bearing mice...
  69. ncbi Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection
    Limin Chen
    Banting and Best Department of Medical Research, University of Toronto, Ontario, Canada
    Gastroenterology 128:1437-44. 2005
    ..A large proportion of patients do not respond to therapy for reasons that are unclear. We used gene expression profiling to investigate the molecular basis for treatment failure...
  70. ncbi Factors affecting the accelerated blood clearance of polyethylene glycol-liposomes upon repeated injection
    P Laverman
    Department of Nuclear Medicine, University Medical Center Nijmegen, Nijmegen, The Netherlands
    J Pharmacol Exp Ther 298:607-12. 2001
    ..Therefore, these findings may have a considerable impact on the clinical application of liposomal formulations that are administered repeatedly...
  71. ncbi Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin
    Peter Ferenci
    Medical University of Vienna, Vienna, Austria
    J Hepatol 43:425-33. 2005
    ..Prediction of sustained virological response (SVR) during treatment would allow clinicians to identify patients most likely to benefit from therapy...
  72. ncbi Poly(ethylene oxide)-block-poly(L-amino acid) micelles for drug delivery
    Afsaneh Lavasanifar
    Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta T6G 2N8, Canada
    Adv Drug Deliv Rev 54:169-90. 2002
    ..PEO-b-PLAA micelles may be advantageous in terms of safety, stability, and scale-up...
  73. ncbi Surface modification of superparamagnetic magnetite nanoparticles and their intracellular uptake
    Yong Zhang
    Department of Materials Science and Engineering, University of Washington, Seattle 98195 2120, USA
    Biomaterials 23:1553-61. 2002
  74. ncbi Accelerated blood clearance (ABC) phenomenon upon repeated injection of PEGylated liposomes
    Tatsuhiro Ishida
    Department of Pharmacokinetics and Biopharmaceutics, Subdivision of Biopharmaceutical Sciences, Institute of Health Biosciences, The University of Tokushima, 1 78 1, Sho machi, Tokushima 770 8505, Japan
    Int J Pharm 354:56-62. 2008
  75. ncbi Structure and design of polymeric surfactant-based drug delivery systems
    V P Torchilin
    Department of Pharmaceutical Sciences, Bouve College of Health Sciences, Northeastern University, 360 Huntington Avenue, Boston, MA 02129, USA
    J Control Release 73:137-72. 2001
    ..Their in vitro and in vivo properties are discussed and the results of the initial animal experiments are presented...
  76. ncbi Formulation of Docetaxel by folic acid-conjugated d-α-tocopheryl polyethylene glycol succinate 2000 (Vitamin E TPGS(2k)) micelles for targeted and synergistic chemotherapy
    Yu Mi
    Department of Chemical and Biomolecular Engineering, National University of Singapore, Block E5, 02 11, 4 Engineering Drive 4, Singapore 117576, Singapore
    Biomaterials 32:4058-66. 2011
  77. ncbi Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study
    Michael E Weinblatt
    Harvard Medical School, Division of Rheumatology, Immunology and Allergy, Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA
    Rheumatology (Oxford) 51:2204-14. 2012
    ..To investigate the efficacy and safety of certolizumab pegol (CZP) in a broad population of patients with active RA...
  78. pmc The parallel G-quadruplex structure of vertebrate telomeric repeat sequences is not the preferred folding topology under physiological conditions
    Robert Hänsel
    Institute of Biophysical Chemistry and Center for Biomolecular Magnetic Resonance, Goethe University, Max von Laue Str 9, 60438 Frankfurt Main, Germany
    Nucleic Acids Res 39:5768-75. 2011
    ..laevis egg extract or in Ficoll resembles results obtained under dilute conditions, PEG promotes the formation of high-order parallel topologies. Our data suggest that PEG should not be used as a MC mimetic...
  79. ncbi Telaprevir and peginterferon with or without ribavirin for chronic HCV infection
    Christophe Hezode
    Assistance Publique Hopitaux de Paris, Henri Mondor Hospital, University of Paris 12 and INSERM Unité 955, Creteil, France
    N Engl J Med 360:1839-50. 2009
    ..Telaprevir is a specific inhibitor of the HCV serine protease and could be of value in HCV treatment...
  80. ncbi UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients
    P Ramachandran
    Department of Gastroenterology, Aberdeen Royal Infirmary, Aberdeen, UK
    Aliment Pharmacol Ther 35:647-62. 2012
    ..However, the addition of these new agents will increase the complexity of therapeutic regimens, the rates of side-effects and costs...
  81. pmc Influence of anchoring ligands and particle size on the colloidal stability and in vivo biodistribution of polyethylene glycol-coated gold nanoparticles in tumor-xenografted mice
    Guodong Zhang
    Department of Experimental Diagnostic Imaging, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Biomaterials 30:1928-36. 2009
    ..Thus, 20-nm AuNPs coated with TA-terminated PEG(5000) are promising potential drug delivery vehicles and diagnostic imaging agents...
  82. ncbi Peginterferon alfa-2a and ribavirin in Latino and non-Latino whites with hepatitis C
    Maribel Rodriguez-Torres
    Fundacion de Investigacion de Diego, San Juan, Puerto Rico
    N Engl J Med 360:257-67. 2009
    ..We evaluated the effect of Latino ethnic background on the response to treatment with peginterferon alfa-2a and ribavirin in patients infected with HCV genotype 1 who had not been treated previously...
  83. ncbi Systemic delivery of siRNA with cationic lipid assisted PEG-PLA nanoparticles for cancer therapy
    Xian Zhu Yang
    Hefei National Laboratory for Physical Sciences at the Microscale, University of Science and Technology of China, Hefei, Anhui 230027, PR China
    J Control Release 156:203-11. 2011
  84. ncbi Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials
    John S Sundy
    Duke Clinical Research Unit, Duke University Medical Center, Durham, North Carolina, USA
    JAMA 306:711-20. 2011
    ..Pegloticase, monomethoxypoly(ethylene glycol)-conjugated mammalian recombinant uricase, was developed to fulfill this need...
  85. pmc Single nucleotide polymorphism upstream of interleukin 28B associated with phase 1 and phase 2 of early viral kinetics in patients infected with HCV genotype 1
    Charles D Howell
    University of Maryland School of Medicine, Program in Genetics and Genomic Medicine, Baltimore, MD, USA
    J Hepatol 56:557-63. 2012
    ..We studied the relationship between IL28B gene-related SNP rs12979860 and early viral kinetics (day 0-28) during peginterferon and ribavirin treatment, in 173 African Americans (AA) and 188 Caucasian Americans (CA) with HCV genotype 1...
  86. ncbi IL28 variation affects expression of interferon stimulated genes and peg-interferon and ribavirin therapy
    Hiromi Abe
    Laboratory for Digestive Diseases, Center for Genomic Medicine, RIKEN, Hiroshima, Japan
    J Hepatol 54:1094-101. 2011
    ..Expression of IL28 in peripheral blood cells has been reported to be higher in patients with IL28 SNP genotypes associated with favorable response...
  87. ncbi Prediction of response to pegylated interferon plus ribavirin by IL28B gene variation in patients coinfected with HIV and hepatitis C virus
    Juan A Pineda
    Unit of Infectious Diseases, Hospital Universitario de Valme, Seville, Spain
    Clin Infect Dis 51:788-95. 2010
    ..We aimed to assess the predictive ability of variations in the single-nucleotide polymorphism rs12979860 for SVR in HIV/HCV-coinfected patients, regardless of HCV genotype...
  88. pmc Outcome of sustained virological responders with histologically advanced chronic hepatitis C
    Timothy R Morgan
    Division of Gastroenterology, University of California Irvine, Irvine, CA, USA
    Hepatology 52:833-44. 2010
    ..15, 95% CI = 0.06-0.38) or HCC (HR = 0.19, 95% CI = 0.04-0.80) was significant for SVR compared to NR. Laboratory tests related to liver disease severity improved following SVR...
  89. ncbi Amphiphilic block copolymers for drug delivery
    Monica L Adams
    Division of Pharmaceutical Sciences, School of Pharmacy, University of Wisconsin Madison, 777 Highland Avenue, Madison, WI 53705 2222, USA
    J Pharm Sci 92:1343-55. 2003
    ..The purpose of this minireview is to provide a concise, yet detailed, introduction to the use of ABCs and polymeric micelles as delivery agents as well as to highlight current and past work in this area...
  90. ncbi PEGylation of therapeutic proteins
    Simona Jevsevar
    Lek Pharmaceuticals d d, a Sandoz Company, Biopharmaceuticals, Ljubljana, Slovenia
    Biotechnol J 5:113-28. 2010
  91. ncbi Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies
    Alberto Gabizon
    Shaare Zedek Medical Center, Jerusalem, Israel
    Clin Pharmacokinet 42:419-36. 2003
    ..Thus, pegylated liposomal doxorubicin represents a new class of chemotherapy delivery system that may significantly improve the therapeutic index of doxorubicin...
  92. ncbi Pegylated arginine deiminase (ADI-SS PEG20,000 mw) inhibits human melanomas and hepatocellular carcinomas in vitro and in vivo
    Charles Mark Ensor
    Department of Biology, T H Morgan Building and Phoenix Pharmacologics, Inc, Lexington, Kentucky 40503, USA
    Cancer Res 62:5443-50. 2002
  93. ncbi Polyethylenimine-graft-poly(ethylene glycol) copolymers: influence of copolymer block structure on DNA complexation and biological activities as gene delivery system
    Holger Petersen
    Department of Pharmaceutics and Biopharmacy, Philipps University, Ketzerbach 63, D 35032 Marburg, Germany
    Bioconjug Chem 13:845-54. 2002
    ..These results provide a basis for the rational design of block copolymer gene delivery systems...
  94. pmc Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery
    Jianjun Cheng
    Department of Chemical Engineering, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, MA 02139, USA
    Biomaterials 28:869-76. 2007
    ..22%+/-0.07% of injected dose per gram of tissue; mean+/-SD, n=4, p=0.002). The ability to control NP size together with targeted delivery may result in favorable biodistribution and development of clinically relevant targeted therapies...
  95. ncbi Polymorphism near the IL28B gene in Korean hepatitis C virus-infected patients treated with peg-interferon plus ribavirin
    Kwangsoo Lyoo
    Department of Internal Medicine and WHO Collaborating Center on Viral Hepatitis, College of Medicine, The Catholic University of Korea, 137 040 Seoul, Republic of Korea
    J Clin Virol 52:363-6. 2011
    ..Single nucleotide polymorphisms (SNPs) near the IL28B gene have recently been described as predictors of antiviral therapy responses in patients with hepatitis C virus (HCV) genotype-1...
  96. ncbi Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections
    Graham R Foster
    Queen Marys University of London, Blizard Institute of Cellular and Molecular Science, London, UK
    Gastroenterology 141:881-889.e1. 2011
    ..We evaluated antiviral activity of 2 weeks therapy with telaprevir alone, peginterferon alfa-2a and ribavirin (PR), or all 3 drugs (TPR) in treatment-naïve patients with chronic hepatitis C virus (HCV) genotype 2 or 3 infections...
  97. ncbi Multifunctional polymeric micelles with folate-mediated cancer cell targeting and pH-triggered drug releasing properties for active intracellular drug delivery
    Younsoo Bae
    Department of Materials Science and Engineering, Graduate School of Engineering, The University of Tokyo, 7 3 1 Hongo, Tokyo, Japan
    Mol Biosyst 1:242-50. 2005
    ..Consequently, these findings would provide one of the most effective approaches for cancer treatment using intracellular environment-targeting supramolecular drug carriers...
  98. ncbi Efficacy of transferrin-conjugated paclitaxel-loaded nanoparticles in a murine model of prostate cancer
    Sanjeeb K Sahoo
    Department of Pharmaceutical Sciences, Nebraska Medical Center, Omaha, NE 68198 6025, USA
    Int J Cancer 112:335-40. 2004
    ..In conclusion, sustained release NPs demonstrated greater antitumor activity following their conjugation to Tf ligand...
  99. ncbi PEGylation significantly affects cellular uptake and intracellular trafficking of non-viral gene delivery particles
    Swaroop Mishra
    Chemical Engineering, California Institute of Technology, Pasadena, CA 91125, USA
    Eur J Cell Biol 83:97-111. 2004
  100. ncbi Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells
    Omid C Farokhzad
    Department of Anesthesiology, Brigham and Women s Hospital, Boston, Massachusetts, USA
    Cancer Res 64:7668-72. 2004
    ..To our knowledge, this represents the first report of targeted drug delivery with nanoparticle-aptamer bioconjugates...
  101. ncbi Evaluation of pharmacokinetics of 111In-labeled VNB-PEGylated liposomes after intraperitoneal and intravenous administration in a tumor/ascites mouse model
    Yi Yu Lin
    Biomedical Imaging and Radiological Sciences, National Yang Ming University, Taipei, Taiwan, Republic of China
    Cancer Biother Radiopharm 24:453-60. 2009
    ..v. route. This study demonstrates that i.p. administration is a better approach than i.v. injection for IVNBPL, when applied to the treatment of i.p. malignant disease in a tumor/ascites mouse model...

Research Grants72

  1. Brain Delivery of Nanoformulated Superoxide Dismutase
    Erin G Rosenbaugh; Fiscal Year: 2013
    ..In addition to the proposed scientific research, this fellowship will support the applicant's participation in nanotechnology-based coursework and career development. ..
  2. Long-Acting G-CSF Analog for Treating ARS
    GEORGE NORBERT COX; Fiscal Year: 2013
    ..The drug should prove useful for treating other diseases for which G-CSF is used as a therapy, such as neutropenia resulting from chemotherapy use in cancer patients. ..
  3. Hepatic Lipase and HCV Infection
    Tianyi Wang; Fiscal Year: 2010
    ..Such knowledge is critical for the future development of novel antiviral therapies. ..
  4. Gold Nanoparticle Assisted Delivery of Cancer Vaccines and Immune Stimulants
    Adam Lin; Fiscal Year: 2013
    ..This design would dramatically lower the cost of immunotherapy compared cellular vaccines. They are easily synthesized, versatile and can potentially target later stage cancers by using inducing anti-tumor immunity over the whole body. ..
  5. Fully Biodegradable Polymersome-encapsulated Hemoglobin as a Novel Nanoparticle-b
    ..Significant additional advantages will be a tremendous cost savings to the health care system in reduced operating costs, as well as enormous job creation and economic stimulus. ..
    Kevin M Smith; Fiscal Year: 2013
    ..The full potential can be realized only when new drugs with higher cellular selectivity and specificity are discovered, their mechanisms of biological action investigated, and their efficacy evaluated relative to existing modalities. ..
  7. Long-Acting G-CSF analogs for treating acute radiation syndrome
    GEORGE NORBERT COX; Fiscal Year: 2010
    ..Our long-acting G-CSF analog may prove useful for improving survival in people exposed to an otherwise lethal dose of radiation as a result of a radiological/nuclear disaster. ..
  8. Extracellular Scaffold Elasticity and Binding Sites in Acinar Differentiation
    Melinda Larsen; Fiscal Year: 2013
    ..polymerase chain reaction;PEG-DMA, PEG-dimethylacrylate;PEG-TMA, PEG-trimethylacrylate;OMMA, oxiran-2-ylmethyl methacrylate;POMO, 2-((prop-2-ynyloxy)methyl)oxirane;SMG, submandibular salivary gland;transepithelial resistance, TER ..
  9. Cell Free O2 Carriers: Cerebrovascular Control and Stroke
    RAYMOND CHARLES KOEHLER; Fiscal Year: 2013
  10. Multifunctional nanoparticles to improve treatment of human glioblastoma
    Miqin Zhang; Fiscal Year: 2013
    ..The expanded health relevance of this research is that the NPs with BBB penetration ability may also facilitate the delivery of therapeutic agents to brain metastases from a variety of tumors. ..
    CHARLES POULTER; Fiscal Year: 2009
    ..This approach can also be used to regio- and chemoselectively attach proteins to other molecules, and offers a new approach for synthesis of clinically useful protein-polyethylene glycol conjugates. ..
  12. 1H MRI based nanosensors for imaging tumor oxygenation
    Vikram D Kodibagkar; Fiscal Year: 2010
    ..Although we study tumors, the technique developed here has potential applications in a wide range of diseased states and can be applied to study basic physiology and oxygen consumption in tissue as well. ..
  13. Phospholipid Nanocarriers Improve Chemotherapy by Targeted Drug Delivery
    Hayat Onyuksel; Fiscal Year: 2010
    Suresh K Joseph; Fiscal Year: 2010
  15. Brain Tumor-Penetrating Nanoparticle Delivery with MR-Guided Focused Ultrasound
    Richard J Price; Fiscal Year: 2013
    ..Our next step would be to test the safety of the MR-guided BPN delivery approach in large animals (pig) using the University of Virginia's clinical Insightec Exablate system, followed by the initiation of a clinical trial. ..
  16. Non-viral gene delivery to neural progenitor cells in the SVZ
    Suzie H Pun; Fiscal Year: 2012
    ..The developed technology would have broad significance as vehicles to deliver therapeutic genes for CNS disorders. ..
  17. Long-acting VIP formulations for the treatment of chronic inflammatory diseases
    Sandra Reichstetter; Fiscal Year: 2010
    ..Rapid degradation and side effects at high dose have so far limited VIP use in humans. In this project VIP will be formulated into forms that will deal with these problems that will allow its universal use in many human diseases. ..
    CHARLES DALE POULTER; Fiscal Year: 2013
    ..Research funded by this proposal studies the enzyme catalysts that construct the basic carbon skeletons of isoprenoid molecules and the development of biotechnological applications based these enzymes. ..
  19. Myelin Composition Influence on Bilayer Interactions in Multiple Sclerosis
    Jacob N Israelachvili; Fiscal Year: 2010
  20. Integrin Targeted Therapy for the Treatment of Ovarian Cancer
    FRANK CALZONE; Fiscal Year: 2013
    ..Further, this translational research has the capability of impacting the morbidity associated with ovarian cancer by preventing the formation of post-surgical adhesions. ..
  21. RAMP Mediated Gene Delivery
    Kevin G Rice; Fiscal Year: 2012
  22. Nanoconjugate based on polymalic acid for brain tumor treatment
    Julia Y Ljubimova; Fiscal Year: 2013
    ..The nanoplatform was developed to inhibit the synthesis of several tumor specific targets that play a significant role in tumor growth, invasion and metastasis, but previously could not be blocked by conventional drugs. ..
  23. Nucleolin-mediated cell entry of DNA nanoparticles
    Pamela B Davis; Fiscal Year: 2010
    ..In addition, the non-degradative pathway they follow in the cell is probably shared by some pathogens. Further understanding of this route may be important in regulating it. . ..
  24. Surface-modified pharmaceutical nanocarriers for subcellular targeting
    Vladimir P Torchilin; Fiscal Year: 2012
  25. Engineering fibrin polymers for enhanced angiogenesis
    THOMAS HARRISON BARKER; Fiscal Year: 2013
    ..This project will have direct relevance to wound healing and regenerative medicine by establishing new methods to manipulate fibrin for specific clinical outcomes. ..
  26. Mechanisms of Renal Protection with Volatile Anesthetics
    H Thomas Lee; Fiscal Year: 2013
    ..As such, our proposal may identify novel therapeutic targets (e.g., IL-11) and novel therapeutics (polyethylene glycol-conjugated IL-11) to reduce complications of AKI and lead to a radical reduction in mortality and morbidity. ..
  27. Micellar Nanocarriers with Controlled Multivalent Ligand Presentation
    Ting Xu; Fiscal Year: 2013
    ..Proposed studies may potentially lead to effective therapeutics with the combined advantages of both passive targeting via EPR effect and active targeting for breast tumors. ..
  28. HIV neutralizing antibodies induced by chemically modified MPR epitopes
    Francis C Szoka; Fiscal Year: 2012
    ..This unusual approach could provide a widely applicable epitope design strategy for development of vaccines to prevent infectious disease such as HIV. ..
  29. Renally Excreted Multimodal Core-Shell Silica Nanoparticles as Tumor-Selective Ra
    Ulrich Wiesner; Fiscal Year: 2013
    ..The efficiency of probe translation to the clinic may additionally be improved based upon the establishment of generalized templates for small ligand targeting platforms. ..
  30. Retrievable Blood Oxygen Carrier System
    Agnes E Ostafin; Fiscal Year: 2012
  31. A new class of biodegradable synthetic biomaterial for seroma prevention
    Michael Craven; Fiscal Year: 2012
    ..The current STTR funded research effort aims to advance the development of a new biodegradable material for the prevention of seroma and thereby improve patient health through improved surgical outcomes. ..
  32. Size-tunable cancer nanotherapeutics
    Juntao Luo; Fiscal Year: 2013
    ..Finally, the in vivo toxicity and anti-tumor properties of the optimized Nanoxane and ligand-nanoxanes will be evaluated in animal models. ..
  33. Porphyrin Conjugates and EGFR
    ALECIA MICHELLE MCCALL; Fiscal Year: 2011
    ..25-35 This research, then, is advantageous in that fluorescent porphyrin-based conjugates be used to selectively and efficiently label CRC tumor foci, which has been illustrated by previous research in our group. ..
  34. Optimizing Bioactive Hydrogels to Control Angiogenesis and Inflammation in Functi
    JOACHIM B KOHN; Fiscal Year: 2010
    ..To overcome the difficulties in studying inflammatory and angiogenic responses to biomaterials, several high risk in vitro and in vivo methods will be utilized. ..
  35. Mechanisms of fibril formation in light chain amyloidosis
    DOUGLAS J MARTIN; Fiscal Year: 2011
    ..This knowledge will lead to the development of therapeutic strategies to treat the disease. We hope that insights gained from the study of light chain amyloidosis will have application in other amyloid-forming disorders. ..
  36. Novel nanoparticles for siRNA delivery
    Leaf Huang; Fiscal Year: 2013
    ..The other is to transport siRNA to tumors with not-so-leaky vasculature. If successful, the project will significantly advance siRNA as cancer therapeutics. ..
  37. Fibrous-Hydrogel Composites for Cartilage Repair in an Osteoarthritic Environment
    MATTHEW AVERY GIBSON; Fiscal Year: 2013
    ..The aims of this proposal seek to develop a novel technology platform for the treatment of cartilage defects both in a healthy joint and in the context of a diseased joint environment. ..
  38. Nanocarrier-formulated NF-kB inhibitors for Inflammatory diseases
    GERARDO M CASTILLO; Fiscal Year: 2012
    ..Our goal for this project is to develop a product for the treatment for chronic inflammatory diseases that will lead to FDA approved treatment for humans. ..
  39. Layer-by-layer nanocarriers for highly efficient solubilization of insoluble drug
    Vladimir P Torchilin; Fiscal Year: 2013
    ..The approach will be applied to several poorly soluble anticancer drugs, and the nanocolloids obtained will be additionally modified by various ligands to make them long-circulating, targeted, and capable of intracellular penetration. ..
  40. Development of a new Imaging Platform for Pharmaceutical and Biomedical applicati
    Lynne S Taylor; Fiscal Year: 2012
    ..In this research proposal, we will focus on demonstrating proof of concept of the nanoscale IR platform to fully characterize the micro- and nanostructure of drug-polymer systems where Prof Taylor of Purdue is an expert. ..
  41. Functionalized Micellar Nanocarriers for Targeted Cancer Therapy
    Chalet Tan; Fiscal Year: 2010
    ..Importantly, the proposed nanocarriers are also engineered to delivery anticancer drugs into cancer stem cells, a rare population of cancer cells in the tumor which are known to be resistant to drug therapy and cause tumor recurrence. ..
  42. Mussel-inspired self-healing hydrogels for vascular tissue repair
    ..We propose to develop materials that have the ability to self-heal, which are inspired by the mussel byssal thread, and may prove to be good tissue replacements for small vessels. ..
  43. Functional Deimmunization of Therapeutic Proteins
    Chris Bailey-Kellogg; Fiscal Year: 2013
    ..Successfully achieving these aims will yield broadly applicable algorithms for engineering powerful and immune-tolerant therapeutic proteins. ..
  44. Development of materials to release bioactive lipids
    Donald L Elbert; Fiscal Year: 2010
    ..Aim 3: Demonstrate that enzymatic production allows delivery of S1P from nanoscale PEG coatings. Aim 4: Evaluate the safety and efficacy of S1 P-releasing PEG coatings containing RGD-peptide in the rat carotid artery. ..
  45. Passivating Proteins in Implantable Glucose Sensors
    W Ward; Fiscal Year: 2004
    ..8. A histologic evaluation will be performed to assess the effect of passivating proteins and antibody blocked fibrinogen on the nature of the foreign body capsule. ..
  46. Dynamically Responsive Bioreactors for Cartilage Regeneration
    Stephanie J Bryant; Fiscal Year: 2013
    ..Findings from this grant will lay the foundation for seeking competitively a NIH R01 and to pursue their (pre)clinical utility. ..
  47. Dvelopment of multi-component peptide vehicles for in vivo neuronal gene therapy
    Ester J Kwon; Fiscal Year: 2010
    ..This research investigates a potential strategy for the treatment of neurodegenerative diseases. It has relevance to public health since neurodegenerative diseases affects over 20 million individuals worldwide. ..
  48. Improving Efficacy of RNase Cancer Therapy by Pharmacokinetics
    Laura E Strong; Fiscal Year: 2010
    ..On a worldwide basis, cancer is responsible for 12.5% of deaths. New cases of cancer are expected to rise to 16M/year in 2020, up from 11M /yr in 2002. Cancer-related deaths are anticipated to rise from 6.7M to 10M over the same period. ..
  49. A novel bioengineered technique to rapidly and permanently repair cut PNS nerves
    GEORGE DAVIS BITTNER; Fiscal Year: 2013
    ..abstract_text> ..
  50. Multiplex Nanocarrier-based Hydrogels for Prevention of Vaginal HIV Transmission.
    Patrick J Sinko; Fiscal Year: 2012
    ..abstract_text> ..
  51. In Situ Regeneration of Bioactive Surfaces: Rechargeable Anti-thrombogenic Films
    Elliot Chaikof; Fiscal Year: 2013
  52. Nanoparticle delivery system for antiturberculosis drug
    Leonid Heifets; Fiscal Year: 2004
    ..abstract_text> ..
  53. Cancer Margin Detection using Infrared Spectroscopy and Plasmon Resonance
    Charles L Hitchcock; Fiscal Year: 2013
  54. CT Monitoring of Angiogenesis
    Benjamin M Yeh; Fiscal Year: 2010
  55. Visible light-cured tissue engineering polymers filled with bioactive glass
    John C Mitchell; Fiscal Year: 2010
    ..g., skin and muscles. This will be crucial to the use of less invasive surgery in tissue and organ repair, minimizing damage to surrounding tissues, and reducing recovery time and its associated expenses. ..
  56. Site-Specific Growth of Stealth Polymer from Peptide Therapeutics
    Ashutosh Chilkoti; Fiscal Year: 2013
  57. Maximizing siRNA Function through Mechanism-based Sequence and Vehicle Design
    STEPHEN PATRICK WALTON; Fiscal Year: 2013
    ..The proposed work will address two of these important steps to provide guidelines for the design of highly-active, highly-specific therapeutics based on RNAi. ..
  58. Mucus-penetrating nanoparticles for sustained microbicide delivery
    Justin Hanes; Fiscal Year: 2009
  59. XTENylation of enfuvirtide to generate a bio-better product with improved dosing
    Volker Schellenberger; Fiscal Year: 2012
    ..Here, we propose to use our XTEN technology to make a better version of enfuvirtide that is easier to use, causes fewer side effects, and is less expensive so that it can be taken by more patients. ..
    Marcos Intaglietta; Fiscal Year: 2009
    ..Strategies for optimal follow up of plasma resuscitation and exchange with blood transfusion will be investigated. ..
  61. Preclinical Development of Uricase-PEG 20
    JOHN BOMALASKI; Fiscal Year: 2002
    ..uricase-PEG 20 is formulated with polyethylene glycol (PEG), a technology known to reduce the antigenicity of heterologous proteins. ..
    DOMINICK CINTI; Fiscal Year: 1991
    ..Insights into these proposed aims will provide significant contributions to our fundamental understanding of lipid metabolism...
  63. Acute Phase Treatment of Spinal Cord Injury Using Hydrogel Blends Loaded with Glu
    Ryan Gilbert; Fiscal Year: 2009
    ..The research described in this proposal will determine if hydrogels loaded with glutathione and polyethylene glycol are more effective at reducing secondary injury than bolus injections of these agents in a rat spinal cord injury model. ..
  64. Stem cells as vehicles for therapeutic nanoparticle delivery to breast cancer
    Deryl Troyer; Fiscal Year: 2009
    ..Once our hypothesis is proven correct, this procedure will be applied to human patients in the future. Therefore, this study should significantly contribute to improve public health. ..
    TIMOTHY FISHER; Fiscal Year: 2003
    ..g., alloimmunized rabbit model, xenotransfusions) methods. An interactive approach to these aims is proposed; their successful achievement should yield important new data and improved health care in SCD. ..
  66. Mining the Structural Genomics Initiative for Disorder
    A Dunker; Fiscal Year: 2009
    ..Alsoof importance is that this workwill significantly increase the sequence-function informationobtained from the structural genomics initiative with very little incremental increase over the current investment. ..
    Kevin Dybvig; Fiscal Year: 1993
  68. Glycine rich sequences with pharmacokinetic enhancing properties of PEG polymers
    Volker Schellenberger; Fiscal Year: 2009
    ..These rPEGs can be directly fused to protein pharmaceuticals to increase their serum half-life. We will validate rPEG technology by developing a long-acting version of human growth hormone for the treatment of dwarfism in children. ..
    Vladimir Torchilin; Fiscal Year: 2007
    ..unreadable] [unreadable]..
    NIKOLAOS PEPPAS; Fiscal Year: 1999
    ..study the mucoadhesive behavior of hydrophilic polymer drug carriers that are modified by the addition of polyethylene glycols, as further described by their abstract: "The primary goal of bioadhesive controlled drug delivery is to ..
    Robert Whalen; Fiscal Year: 2000
    ..The new urinary catheter has the potential to reduce hospital costs associated with the management of catheter associated infections. ..
  72. Shape Specific, Enzyme-Responsive, Nano-Imprinted Particles for Drug Delivery
    Krishnendu Roy; Fiscal Year: 2009
    ..In addition the particles would be able to target tumor cells and deliver the cargo (drugs or imaging agents) to the tumor primarily in response to a disease-specific signal, e.g. enzyme up regulation. ..